Immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte-associated protein 4 and anti-programmed cell death 1 (PD-1) antibodies, are currently being used clinically for lung cancer therapy [1, 2]. Here, PDCD1 is linked to lung cancer.